{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"EKSO","limit":50},"count":50,"signals":[{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":65,"context":"iness combination with Applied Digital Corporations cloud computing business, Applied Digital Cloud, may not be completed on the terms or timeline currently contemplated or at all, which could have a material adverse effect on our business, financial condition and results of operations. We are incurring material costs in connection with our evaluation of strategic transactions, including such proposed business combinati","filed_date":"2026-02-23","accession":"0001437749-26-005086","full_text":"https://origin.rootz.global/static/filing/0001437749-26-005086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":80,"context":"to such time and actually received, deposited or available. Closing Date means the date on which Closing occurs. Cloud Common Stock means the common stock of Cloud, par value $0.001 per share. Cloud Material Adverse Effect means, with respect to Cloud, any Effect that, individually or taken together with all other Effects that have occurred prior to the date of determination of the occurrence of the Cloud Material Adve","filed_date":"2026-02-17","accession":"0001437749-26-004205","full_text":"https://origin.rootz.global/static/filing/0001437749-26-004205.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ified, except, in the case of this clause (iii), where failure to be so qualified or in good standing, individually or in the aggregate, has not and would not reasonably be expected to have a Company Material Adverse Effect. True and accurate copies of the Restated Articles of Incorporation of the Company (as amended or modified from time to time prior to the date hereof, the Articles of Incorporation) and the amended a","filed_date":"2026-01-22","accession":"0001437749-26-001774","full_text":"https://origin.rootz.global/static/filing/0001437749-26-001774.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":29,"context":"ts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. 2 Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $4.81, subject to adju","filed_date":"2025-10-30","accession":"0001437749-25-032276","full_text":"https://origin.rootz.global/static/filing/0001437749-25-032276.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":37,"context":"ch number by the Split Ratio, if the Reverse Stock Split Proposal is approved and implemented) (\"Proposal Three\"); |  | |  4. |  To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement (\"Proposal Four\"); |  | |  5. |  To ratify the appointment of WithumSmith+Brown PC as the Companys independent auditors for the year ending December 31, 2025 (\"Pr","filed_date":"2025-04-10","accession":"0001437749-25-011679","full_text":"https://origin.rootz.global/static/filing/0001437749-25-011679.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":59,"context":"our current products or new products that we may develop in the future, demand for such products may decline or may not grow as we expect, which could limit our ability to generate revenue and have a material adverse effect on our financial condition, results of operations and cash flow. The coverage and reimbursement market may be additionally impacted by future legislative changes. There are increasing efforts by gove","filed_date":"2025-03-03","accession":"0001437749-25-005913","full_text":"https://origin.rootz.global/static/filing/0001437749-25-005913.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":29,"context":"t or other restriction. Lock-Up Agreements means the lock-up agreements that are delivered on the date hereof by each of the Companys officers and directors, in the form of Exhibit A attached hereto. Material Adverse Effect means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business or condition","filed_date":"2024-09-03","accession":"0001437749-24-028253","full_text":"https://origin.rootz.global/static/filing/0001437749-24-028253.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":29,"context":"t or other restriction. Lock-Up Agreements means the lock-up agreements that are delivered on the date hereof by each of the Companys officers and directors, in the form of Exhibit A attached hereto. Material Adverse Effect means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business or condition","filed_date":"2024-08-28","accession":"0001437749-24-027894","full_text":"https://origin.rootz.global/static/filing/0001437749-24-027894.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":48,"context":"stock authorized for issuance pursuant to awards under our 2014 Equity Incentive Plan prior to its expiration); |  | |  |  3. |  To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement; |  | |  |  4. |  To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive off","filed_date":"2024-04-26","accession":"0001437749-24-013418","full_text":"https://origin.rootz.global/static/filing/0001437749-24-013418.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":58,"context":"our current products or new products that we may develop in the future, demand for such products may decline or may not grow as we expect, which could limit our ability to generate revenue and have a material adverse effect on our financial condition, results of operations and cash flow. The coverage and reimbursement market may be additionally impacted by future legislative changes. There are increasing efforts by gove","filed_date":"2024-03-04","accession":"0001437749-24-006423","full_text":"https://origin.rootz.global/static/filing/0001437749-24-006423.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":27,"context":"or other restriction. Lock-Up Agreement means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers, in the form of Exhibit A attached hereto. 2 Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Per Share Purchase Price equals $1.55, subject to adju","filed_date":"2024-01-16","accession":"0001437749-24-001348","full_text":"https://origin.rootz.global/static/filing/0001437749-24-001348.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":38,"context":"ommon stock authorized for issuance pursuant to awards granted thereunder from 2,524,286 shares to 3,724,286 shares | | | | 3. | To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement | | | | 4. | To ratify the appointment of WithumSmith+Brown PC as the Companys independent auditors for the year ending December 31, 2023 and | | | | 5. | To tran","filed_date":"2023-04-28","accession":"0001549084-23-000024","full_text":"https://origin.rootz.global/static/filing/0001549084-23-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":36,"context":"rity statutes or regulations could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our results or operations.  Patient Protection and Affordable Care Act In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other","filed_date":"2023-03-28","accession":"0001549084-23-000011","full_text":"https://origin.rootz.global/static/filing/0001549084-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":32,"context":"ommon stock authorized for issuance pursuant to awards granted thereunder from 1,974,286 shares to 2,524,286 shares | | | | 3. | To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement | | | | 4. | To ratify the appointment of WithumSmith+Brown PC as the Companys independent auditors for the year ending December 31, 2022 and | | | | 5. | To tran","filed_date":"2022-04-29","accession":"0001549084-22-000021","full_text":"https://origin.rootz.global/static/filing/0001549084-22-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":19,"context":"y evolving, however, so the extent to which the COVID-19 outbreak will impact business and the economy is uncertain. Accordingly, consequences stemming from the ongoing COVID-19 pandemic could have a material adverse effect on our business, financial condition, results of operations and cash flows. We have a limited operating history upon which investors can evaluate our future prospects.  Although we were incorporated","filed_date":"2022-02-24","accession":"0001549084-22-000006","full_text":"https://origin.rootz.global/static/filing/0001549084-22-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":27,"context":"nd until their respective successors are elected and qualified, or until their earlier death, resignation or removal; | | | 2. | To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement; | | | 3. | To ratify the appointment of OUM & Co., LLP as the Companys independent auditors for the year ending December31, 2021; and | | | 4. | To transact such","filed_date":"2021-04-29","accession":"0001140361-21-014969","full_text":"https://origin.rootz.global/static/filing/0001140361-21-014969.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":19,"context":"y evolving, however, so the extent to which the COVID-19 outbreak will impact business and the economy is uncertain. Accordingly, consequences stemming from the ongoing COVID-19 pandemic could have a material adverse effect on our business, financial condition, results of operations and cash flows. We have a limited operating history upon which investors can evaluate our future prospects.  Although we were incorporated","filed_date":"2021-02-25","accession":"0001549084-21-000012","full_text":"https://origin.rootz.global/static/filing/0001549084-21-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":34,"context":"awards granted under our Amended and Restated 2014 Equity Incentive Plan from 1,174,286 shares to 1,974,286 shares | | | | 3. | To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement | | | | 4. | To ratify the appointment of OUM Co., LLP as the Companys independent auditors for the year ending December 31, 2020 and | | | | 5. | To transact suc","filed_date":"2020-11-12","accession":"0001549084-20-000045","full_text":"https://origin.rootz.global/static/filing/0001549084-20-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":26,"context":"to such term in Section 3(v). Issuer Free Writing Prospectus shall mean an issuer free writing prospectus, as defined in Rule 433. Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(t). Maximum Amount shall have the meaning ascribed to such ter","filed_date":"2020-10-09","accession":"0001549084-20-000033","full_text":"https://origin.rootz.global/static/filing/0001549084-20-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":15,"context":"quest Form as provided in Section 2.1  (b)Borrower shall be in compliance with Section 6.6 hereof  Ekso Bionics, Inc. LSA EXECUTION 4. (c)in Banks sole but reasonable discretion, there has not been a Material Adverse Effect and (d)the representations and warranties contained in Section 5 shall be true and correct in all material respects on and as of the date of such Loan AdvancePaydown Request Form and on the effective","filed_date":"2020-08-21","accession":"0001549084-20-000027","full_text":"https://origin.rootz.global/static/filing/0001549084-20-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":26,"context":"manufacturing and sale of the foregoing products in the JV Territory. We will also be reliant on our Joint Venture Partners to fund the China JV in the future, and their failure to do so could have a material adverse effect on the ability of the China JV to effectively manufacture and sell products. Even to the extent the China JV is successful in manufacturing and selling products, aside from a royalty fee based on a m","filed_date":"2020-02-27","accession":"0001549084-20-000005","full_text":"https://origin.rootz.global/static/filing/0001549084-20-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":18,"context":"of common stock, and (ii) authorize our Board of Directors to file only one such amendment, as determined by our Board of Directors in the manner described herein, and to abandon each amendment not selected by our Board of Directors. Our Board of Directors believes that stockholder approval of amendments granting our Board of Directors this discretion, rather than approval of a specified ratio, provides our Board of Directors w","filed_date":"2020-02-10","accession":"0001140361-20-002635","full_text":"https://origin.rootz.global/static/filing/0001140361-20-002635.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":38,"context":"nt, the Time of Sale Prospectus and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders e","filed_date":"2019-05-24","accession":"0001144204-19-028075","full_text":"https://origin.rootz.global/static/filing/0001144204-19-028075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"y effective March 9, 2018. | | | | (1) | Option becomes exercisable as to 25% of the total number of shares on March 9, 2019, and thereafter as to 1/36th of the remaining shares in equal monthly installments for 36 months. | | | | (2) | Option became exercisable as to 1/48th of the shares in equal monthly installments starting on January 15, 2014. | | | | (3) | Option became exercisable as to 1/12th","filed_date":"2019-04-30","accession":"0001140361-19-008051","full_text":"https://origin.rootz.global/static/filing/0001140361-19-008051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":37,"context":"wards granted under our Amended and Restated 2014 Equity Incentive Plan from 9,114,285 shares to 12,614,285 shares; | | | | 3. | To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in the Proxy Statement; | | | | 4. | To ratify the appointment of OUM & Co., LLP as the Companys independent auditors for the year ending December 31, 2019; and | | | | 5. | To transact","filed_date":"2019-04-30","accession":"0001140361-19-008051","full_text":"https://origin.rootz.global/static/filing/0001140361-19-008051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":22,"context":"potentially, as certain other countries in Asia, or the JV Territory. We will also be reliant on our Joint Venture Partners to fund the China JV in the future, and their failure to do so could have a material adverse effect on the ability of the China JV to effectively manufacture and sell products. Even to the extent the China JV is successful in manufacturing and selling products, aside from a royalty fee based on a m","filed_date":"2019-02-28","accession":"0001549084-19-000002","full_text":"https://origin.rootz.global/static/filing/0001549084-19-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":18,"context":"nts for some obligations. Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Companys condensed consolidated financial statements. 15.Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share: | | | | | | | | | | | | | |","filed_date":"2018-11-07","accession":"0001628280-18-013896","full_text":"https://origin.rootz.global/static/filing/0001628280-18-013896.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"s described above had a term of ten years and become exercisable as to 25% of the total number of shares on the one-year anniversary of the date of grant, and thereafter vest in 36 equal monthly installments.  If our stockholders ratify the 2014 Plan Increase at the Meeting as outlined in Proposal Three, our Compensation Committee intends to grant additional long-term incentive awards to our named ex","filed_date":"2018-04-30","accession":"0001140361-18-020401","full_text":"https://origin.rootz.global/static/filing/0001140361-18-020401.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":109,"context":"ching a new pulse oximetry platform. From July 1997 to June 2000, Mr. DeLonzor served as Vice President of Research and Development for the hospital products division of Mallinckrodt Pharmaceuticals (acquired by Tyco Healthcare for $4.2 billion), where he was responsible for expanding and maintaining a broad variety of products used by respiratory impaired patients. From July 1990 to July 1997, Mr. DeLonzor also held leadership p","filed_date":"2018-04-30","accession":"0001140361-18-020401","full_text":"https://origin.rootz.global/static/filing/0001140361-18-020401.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":17,"context":"st us could result in our payment of significant monetary damages and/or royalty payments or negatively impact our ability to sell current or future products in the affected category and could have a material adverse effect on our business, cash flows, financial condition or results of operations. **Some of the patents and patent applications in the intellectual property portfolio are not within our complete control, wh","filed_date":"2018-03-13","accession":"0001144204-18-014386","full_text":"https://origin.rootz.global/static/filing/0001144204-18-014386.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"|  |  |  |  |  |  |  9.59 |  |  |  |  6/11/2025 |  |  | |  |  (1) |  Option became exercisable as to 25% of the total number of shares on February 28, 2015, and thereafter vests in equal monthly installments for 36 months. |  | 7 TABLE OF CONTENTS |  |  (2) |  Options became exercisable as to 25% of the total number of shares on February 5, 2016 and thereafter vests in equal monthly installments for","filed_date":"2017-11-24","accession":"0001144204-17-060784","full_text":"https://origin.rootz.global/static/filing/0001144204-17-060784.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":23,"context":"whom disclosure would have been provided pursuant to clause (ii) above but for the fact that the individual was not serving as an executive officer at the end of the most recent fiscal year (each, a named executive officer).  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | |  Name and Principal Position |  |  Year |  |  Salary ($) |  |  Bonus ($) |  |  Option Awards ($)1 |  |  Non-Equity Incentive Plan Compensation (","filed_date":"2017-11-24","accession":"0001144204-17-060784","full_text":"https://origin.rootz.global/static/filing/0001144204-17-060784.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"| | |  | - | | |  | - | | |  | 9.59 | | |  6/11/2025 | | |  | (1) | Option became exercisable as to 25% of the total number of shares on February 28, 2015, and thereafter vests in equal monthly installments for 36 months. | | |  | (2) | Options became exercisable as to 25% of the total number of shares on February 5, 2016 and thereafter vests in equal monthly installments for 36 months. | | | | 18 |","filed_date":"2017-04-28","accession":"0001144204-17-022835","full_text":"https://origin.rootz.global/static/filing/0001144204-17-022835.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":35,"context":"ching a new pulse oximetry platform. From July 1997 to June 2000, Mr. DeLonzor served as Vice President of Research and Development for the hospital products division of Mallinckrodt Pharmaceuticals (acquired by Tyco Healthcare for $4.2 billion), where he was responsible for expanding and maintaining a broad variety of products used by respiratory impaired patients. From July 1990 to July 1997, Mr. DeLonzor also held leadership p","filed_date":"2017-04-28","accession":"0001144204-17-022835","full_text":"https://origin.rootz.global/static/filing/0001144204-17-022835.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":19,"context":"st us could result in our payment of significant monetary damages and/or royalty payments or negatively impact our ability to sell current or future products in the affected category and could have a material adverse effect on our business, cash flows, financial condition or results of operations. **Some of the patents in the intellectual property portfolio are not within our complete control, which could reduce the val","filed_date":"2017-03-15","accession":"0001144204-17-014588","full_text":"https://origin.rootz.global/static/filing/0001144204-17-014588.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":35,"context":"ed by the Board and serve at its pleasure. There is no family relationship between any of our directors, director nominees or executive officers. Except as otherwise disclosed below, no director was selected as a director or nominee pursuant to any arrangement or understanding.  |  |  |  |  |  |  | |  Name |  |  Age |  |  Position |  | |  Directors |  |  |  |  |  | |  Steven Sherman |  |  70 |  |  Director and Chairma","filed_date":"2016-04-25","accession":"0001144204-16-096121","full_text":"https://origin.rootz.global/static/filing/0001144204-16-096121.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"additional 14 investigator-initiated studies currently underway, covering stroke, SCI (complete and incomplete), acquired brain injury, Cerebral Palsy and Multiple Sclerosis with a total patient enrollment goal of over 500. Two studies recently announced in 2016 include: |  | | Robotic Exoskeleton Gait Training during Acute Stroke Rehabilitation Kessler Institute of Rehabilitation; Karen J. Nolan, P","filed_date":"2016-03-14","accession":"0001144204-16-087881","full_text":"https://origin.rootz.global/static/filing/0001144204-16-087881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":20,"context":"st us could result in our payment of significant monetary damages and/or royalty payments or negatively impact our ability to sell current or future products in the affected category and could have a material adverse effect on our business, cash flows, financial condition or results of operations. **Some of the patents in the intellectual property portfolio are not within our complete control, which could reduce the val","filed_date":"2016-03-14","accession":"0001144204-16-087881","full_text":"https://origin.rootz.global/static/filing/0001144204-16-087881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":36,"context":"ed by the Board and serve at its pleasure. There is no family relationship between any of our directors, director nominees or executive officers. Except as otherwise disclosed below, no director was selected as a director or nominee pursuant to any arrangement or understanding. |  Name |  |  Age |  |  Position |  |  Date Named to Board of Directors/as Executive Officer | | |  Directors |  |  |  |  |  |  | | |  Steven","filed_date":"2016-03-14","accession":"0001144204-16-087881","full_text":"https://origin.rootz.global/static/filing/0001144204-16-087881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ed by the Board and serve at its pleasure. There is no family relationship between any of our directors, director nominees or executive officers. Except as otherwise disclosed below, no director was selected as a director or nominee pursuant to any arrangement or understanding.  |  |  |  |  |  |  | |  Name |  |  Age |  |  Position |  | |  Directors |  |  |  |  |  | |  Steven Sherman |  |  69 |  |  Director and Chairma","filed_date":"2015-05-11","accession":"0001144204-15-029053","full_text":"https://origin.rootz.global/static/filing/0001144204-15-029053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":17,"context":"st us could result in our payment of significant monetary damages and/or royalty payments or negatively impact our ability to sell current or future products in the affected category and could have a material adverse effect on our business, cash flows, financial condition or results of operations. | 19 | | | | | **Some of the patents in the intellectual property portfolio are not within our complete control, which could","filed_date":"2015-03-19","accession":"0001144204-15-017256","full_text":"https://origin.rootz.global/static/filing/0001144204-15-017256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ed by the Board and serve at its pleasure. There is no family relationship between any of our directors, director nominees or executive officers. Except as otherwise disclosed below, no director was selected as a director or nominee pursuant to any arrangement or understanding. |  Name |  |  Age |  |  Position |  |  Date Named to Board of Directors/as Executive Officer | | |  Directors |  |  |  |  |  |  | | |  Steven","filed_date":"2015-03-19","accession":"0001144204-15-017256","full_text":"https://origin.rootz.global/static/filing/0001144204-15-017256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":100,"match_count":76,"context":"lts of operations could be negatively impacted.Our inability to market and close the sale of our Legacy Ekso Business that is currently held for sale and treated as discontinued operations may have a material adverse impact on our business and financial condition.Our stock price has been volatile and may continue to be volatile in the future; this volatility may affect your ability to, and the price at which you could,","filed_date":"2026-08-19","accession":"0001628280-26-058018","full_text":"https://origin.rootz.global/static/filing/0001628280-26-058018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":94,"match_count":8,"context":"e applicable countrycash deposit insurancelimits of approximately *$100* at each of the Company's *two* foreign banks. Any foreign exchange lossincurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to ac","filed_date":"2025-10-28","accession":"0001437749-25-031960","full_text":"https://origin.rootz.global/static/filing/0001437749-25-031960.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"strategic_event","strength":93,"match_count":11,"context":"ved as a director in the previous five years. Directors are elected to serve until the next annual meeting of stockholders and until their successors are elected and qualified. Executive officers are appointed by our Board of Directors and serve at its pleasure. There is no family relationship between any of our directors, director nominees or executive officers. Except as otherwise disclosed below, no director was selected as a d","filed_date":"2020-04-28","accession":"0001549084-20-000010","full_text":"https://origin.rootz.global/static/filing/0001549084-20-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":88,"match_count":11,"context":"ther state where the nature of such Loan Partys business or property requires it to be qualified to do business, except where the failure to be so qualified could not reasonably be expected to have a Material Adverse Effect, and (ii) has the power, authority and legal right to own its property and carry on the business now being conducted by it and to engage in the transactions contemplated by this Note. This Agreement","filed_date":"2025-09-17","accession":"0001437749-25-029285","full_text":"https://origin.rootz.global/static/filing/0001437749-25-029285.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"33.33% of the total number of stock awarded annually. | | | (3) | Option became exercisable as to 148th of the total number of shares on November 15, 2019, and will continue to in equal monthly installments on the same day of each month thereafter. | | | (4) | Restricted stock award vesting November 15, 2020 vesting as to 25% of the total number of stock awarded, and thereafter as to 14th of the rem","filed_date":"2023-04-28","accession":"0001549084-23-000024","full_text":"https://origin.rootz.global/static/filing/0001549084-23-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":78,"match_count":6,"context":"ularly exceed the applicable countrycash deposit insurancelimits of approximately *$100* at each of the Company's *two* foreign banks. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. The Company's cash balances held in domestic banks are deposited into accounts at various institutions with each balance u","filed_date":"2024-07-29","accession":"0001437749-24-023765","full_text":"https://origin.rootz.global/static/filing/0001437749-24-023765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"risk_factor","strength":78,"match_count":6,"context":"nts for some obligations. Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Companys condensed consolidated financial statements. 29 [Table of Contents](#if6a34005b2e5486094d2cc59d61ae147_7) Ekso Bionics Holdings, Inc. Notes to Condensed Consolidated Financial Stateme","filed_date":"2020-07-30","accession":"0001549084-20-000025","full_text":"https://origin.rootz.global/static/filing/0001549084-20-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EKSO","company":"EKSO BIONICS HOLDINGS, INC.","exchange":"Nasdaq","sector":"General Industrial Machinery & Equipment, NEC","signal_type":"ai_adoption","strength":77,"match_count":9,"context":"essarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials. Conducting successful clinical studies requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on","filed_date":"2015-03-19","accession":"0001144204-15-017256","full_text":"https://origin.rootz.global/static/filing/0001144204-15-017256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"f5a1d822bdcada90dcad5e17585c4e4ad3b52e228f44cf4d675a5fe1fc2b9dcf","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"bacfb60a398fe602abd54b0a071e97f85d7214c86dbe4c4c282c9c923030d781","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":473,"hourly_limit":500,"remaining":27,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}